Guideline Concordance of Statin Treatment Decisions: A Retrospective Cohort Study
Yael Rachamin1, Stefan Markun1, Thomas Grischott1
1Institute of Primary Care, University of Zurich and University Hospital Zurich, Pestalozzistr. 24, 8091 Zurich, Switzerland.
Abstract:
Guidelines recommend initiation of statins depending on cardiovascular risk and low-density lipoprotein cholesterol (LDL-C) levels. In this retrospective cohort study, we aimed to assess guideline concordance of statin treatment decisions and to find determinants of undertreatment in Swiss primary care in the period 2016-2019. We drew on electronic medical records of 8060 statin-naive patients (50.0% female, median age 59 years) with available LDL-C levels and cardiovascular risk. Guideline concordance was assessed based on the recommendations of the European Society of Cardiology, and multilevel logistic regression was performed to find determinants of undertreatment. We found that statin treatment was initiated in 10.2% of patients (50.0% female, median age 59 years) during one year of follow up. Treatment decisions were classified as guideline-concordant in 63.0%, as undertreatment in 35.8% and as overtreatment in 1.2%. Among determinants of undertreatment were small deviation from LDL-C treatment thresholds (odds ratio per decrease by 1 mmol/L: 2.09 [95% confidence interval 1.87-2.35]), high compared with very high cardiovascular risk (1.64 [1.30-2.05]), female sex (1.31 [1.05-1.64]), and being treated by older general practitioners (per 10 year decrease: 0.74 [0.61-0.90]). In conclusion, undertreatment of patients at high or very high cardiovascular risk was common, but general practitioners considered cardiovascular risk and LDL-C in their treatment decisions.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Bioequivalence Data: Statistical Interpretation
Bioequivalence of Drugs: Drugs with Multiple Indications
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis III: Management

